Diabetes Drugs Boost Heart Failure But ...(ontori believes clinical trials could he...),Health

The counter-argument is that if long trials were required, there would be fewer drugs on the market, and patient's choices would be limited.

"The current approach increases choice, but patients do not have the information they need to make the necessary choices," Montori said. "We cannot be confident that the options we have are associated with more good than harm,"

More information

For more on diabetes drugs, visit the U.S. Food and Drug Administration.

SOURCES: Richard Nesto, M.D., chair, department of cardiovascular medicine, Lahey Clinic Medical Center, Burlington, Mass; Sonal Singh, M.D., assistant professor, internal medicine, Wake Forest University School of Medicine, Winston-Salem, N.C.; Victor Montori, M.D., Mayo Clinic, Rochester, Minn; Steven E. Nissen M.D., chairman, department of cardiovascular medicine, Cleveland Clinic Foundation; Sept. 29, 2007, The Lancet; Sept. 27, 2007, statement, GlaxoSmithKline